Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma.

T2aN0 adjuvant chemotherapy early lung cancer lung adenocarcinoma stage IB

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 12 11 2022
accepted: 13 02 2023
entrez: 17 3 2023
pubmed: 18 3 2023
medline: 18 3 2023
Statut: epublish

Résumé

For patients with T2aN0 stage IB lung adenocarcinoma, benefits of adjuvant chemotherapy remain controversial. Here, we aimed to evaluate such benefits. This retrospective cohort study was conducted on the database of the National Taiwan Cancer Registry. We analyzed patients with T2aN0 stage IB lung adenocarcinoma (re-classified by AJCC 8th edition) diagnosed during the period from January 2011 to December 2017. They were divided into two groups: (1) group 1: tumor <=3 cm with visceral pleural invasion (VPI); (2) group 2: tumor >3 cm, but <=4 cm. Overall survival (OS) and cancer specific survival (CSS) were evaluated. Risk factors for survival were determined. A total of 2,100 patients with T2aN0 stage IB lung adenocarcinoma (1,265 in group 1 and 835 in group 2) were enrolled for study. The proportions of patients receiving adjuvant chemotherapy in group 1 and 2 were 39.1% and 68.6%, respectively. Amongst group 1 patients, adjuvant chemotherapy was not an independent risk factor for OS and CSS. Amongst group 2 patients, high-grade histologic findings and receiving sublobar resection were two risk factors for poorer survival. Adjuvant chemotherapy was also associated with an OS (adjusted hazard ratio (aHR), 0.52; 95% confidence interval (CI), 0.38-0.72; P<0.001) and CSS (aHR, 0.54; 95% CI, 0.37-0.78; p=0.001) benefit regardless of the presence or absence of risk factors. For patients with T2aN0 stage IB lung adenocarcinoma, adjuvant chemotherapy improved OS and CSS in those with tumors >3 cm, but <=4 cm.For patients with tumors <=3 cm with VPI, adjuvant chemotherapy had no survival benefit.

Identifiants

DOI: 10.3389/fonc.2023.1096683 PMID: 36925928 PMC: PMC10011699
pubmed: 36925928
doi: 10.3389/fonc.2023.1096683
pmc: PMC10011699
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1096683

Informations de copyright

Copyright © 2023 Lee, Chiang, Tseng, Zheng, Chen, Chu, Huang, Hsu, Lee, Yang, Liu, Hsia and Chang.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Surg Oncol. 2013 Sep;22(3):156-61
pubmed: 23702313
J Thorac Oncol. 2007 Aug;2(8):706-14
pubmed: 17762336
Chest. 2017 Jan;151(1):193-203
pubmed: 27780786
Chest. 1997 Jun;111(6):1710-7
pubmed: 9187198
JAMA Netw Open. 2022 Mar 1;5(3):e224830
pubmed: 35353165
Lung Cancer. 2011 Jun;72(3):333-9
pubmed: 21111508
J Clin Oncol. 2008 Nov 1;26(31):5043-51
pubmed: 18809614
PLoS One. 2015 Mar 19;10(3):e0120852
pubmed: 25789627
Lancet Oncol. 2006 Sep;7(9):719-27
pubmed: 16945766
Eur J Cardiothorac Surg. 2004 Jul;26(1):173-82
pubmed: 15200998
N Engl J Med. 2005 Jun 23;352(25):2589-97
pubmed: 15972865
J Formos Med Assoc. 2019 May;118(5):856-858
pubmed: 30773272
J Natl Compr Canc Netw. 2021 Mar 02;19(3):254-266
pubmed: 33668021
J Thorac Oncol. 2019 May;14(5):784-792
pubmed: 30664991
J Clin Oncol. 2010 Jan 1;28(1):29-34
pubmed: 19933915
J Thorac Oncol. 2016 Oct;11(10):1729-35
pubmed: 27287414
J Cancer Res Clin Oncol. 2020 Jan;146(1):43-52
pubmed: 31705294
Eur J Cardiothorac Surg. 2022 Jun 15;62(1):
pubmed: 35325098
JAMA Oncol. 2020 Nov 01;6(11):1741-1750
pubmed: 32940636
Int J Cancer. 2006 Aug 15;119(4):955-60
pubmed: 16550600
Lung Cancer. 2021 Nov;161:18-25
pubmed: 34492552
Ann Transl Med. 2021 Sep;9(18):1430
pubmed: 34733982
Eur J Cardiothorac Surg. 2001 Aug;20(2):378-84
pubmed: 11463561
Jpn J Clin Oncol. 2015 Mar;45(3):291-6
pubmed: 25601947
Hepatology. 2014 Jun;59(6):2092-100
pubmed: 24002804
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
N Engl J Med. 2004 Jan 22;350(4):351-60
pubmed: 14736927
J Clin Oncol. 2008 Jul 20;26(21):3552-9
pubmed: 18506026
Chest. 2013 May;143(5 Suppl):e278S-e313S
pubmed: 23649443
Lung Cancer. 2010 Mar;67(3):343-7
pubmed: 19477549
J Natl Cancer Inst. 2003 Oct 1;95(19):1453-61
pubmed: 14519751
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
N Engl J Med. 2020 Oct 29;383(18):1711-1723
pubmed: 32955177
J Surg Oncol. 2014 Aug;110(2):99-106
pubmed: 24788590
Clin Lung Cancer. 2016 Sep;17(5):e45-e56
pubmed: 27133540
J Cancer Res Ther. 2018 Jan;14(1):139-144
pubmed: 29516976

Auteurs

Po-Hsin Lee (PH)

Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
Rong Hsing Research Center For Translational Medicine, National Chung Hsing University, Taichung, Taiwan.

Chun-Ju Chiang (CJ)

Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Taiwan Cancer Registry, Taipei, Taiwan.

Jeng-Sen Tseng (JS)

Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.
Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.

Zhe-Rong Zheng (ZR)

Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.

Kun-Chieh Chen (KC)

Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
School of Medicine, Chung Shan Medical University, Taichung, Taiwan.

Cheng-Hsiang Chu (CH)

Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
School of Medicine, Chung Shan Medical University, Taichung, Taiwan.

Yen-Hsiang Huang (YH)

Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.

Kuo-Hsuan Hsu (KH)

Division of Critical Care and Respiratory Therapy, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.

Wen-Chung Lee (WC)

Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Taiwan Cancer Registry, Taipei, Taiwan.

Tsung-Ying Yang (TY)

Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.

Tsang-Wu Liu (TW)

National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan.

Jiun-Yi Hsia (JY)

School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Division of Thoracic Surgery, Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan.

Gee-Chen Chang (GC)

Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.
Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.

Classifications MeSH